Our research aims to characterize abnormalities in cognitive processes that contribute to the onset and clinical course of serious mental illnesses, particularly psychosis-spectrum disorders, with the goal of advancing mechanistically informed intervention and early detection strategies that prevent functional disability. Our research integrates clinical and cognitive neuroscience methods, including electroencephalography (EEG), neuromodulation, translational behavioral paradigms, and cognitive and pharmacological interventions. 

Current work includes (1) using EEG and functional magnetic resonance imaging (fMRI) to clarify the contribution of deficient early auditory and visual information processing and neuroplasticity mechanisms to cognitive function, clinical outcomes, and treatment response in schizophrenia, (2) identifying EEG-based biomarkers that predict vulnerability for, or confer resilience against, psychosis onset among individuals at clinical high-risk for psychosis (CHR), and (3) testing novel interventions aiming to improve cognition, neuroplasticity, and other symptoms among individuals with the CHR syndrome or those who are experiencing major depression.